ClinicalTrials.gg
CompletedNCT00132496Updated Dec 3, 2009Results posted

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

A Phase 2 interventional study of rabeprazole sodium in Gastroesophageal Reflux Disease, sponsored by Eisai Inc.. Completed at 25 sites in United States. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2009-12-03.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
12 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
19th of 39
111 · median 100
Started
2005
with 6 others
Phase 2
4 of 40
none open now
Registered
1st of 40
by date
Lead sponsor
9 of 40
Eisai Inc.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2005, is one of 4 in phase 2, and was the 1st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 12 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years. The secondary objectives are to assess the efficacy of rabeprazole on the improvement of the symptoms of GERD and to explore the relationship of symptom relief to dose received, based on symptom frequency and severity, antacid use, and quality of life (QOL) measures.

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • GERD
04

Who can participate

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 12 to 16 years with a clinical diagnosis of symptomatic GERD or suspected or endoscopically proven GERD.
  2. Patients who have ever been treated with, or are currently receiving proton pump inhibitors (PPIs),histamine receptor (H2) blockers, or antacids are eligible (as long as they can go off PPIs and H2 blockers for three days prior to dosing, except for cimetidine, which must be discontinued for at least seven days prior to dosing; exclusion criteria 5 and 6). Also, patients should be able to go off PPI therapy for two weeks at the end active drug treatment.
  3. Children with stable asthma/reactive airways disease on stable treatment regimens are eligible.
  4. Children on stable doses of allergy, antiepileptic, antidepressant, and attention deficit disorder medicines are eligible.
  5. Patients must be able and willing to swallow the test drug tablet intact. The ability of the child to swallow an intact tablet must be confirmed by the site at Screening.
  6. The patient is willing and able to give assent to participate.
  7. The patient's parent or guardian gives written .
  8. Post-pubertal females will be required to be abstinent during the course of the study.
  9. Clinically insignificant laboratory findings.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of significant hepatic, renal, respiratory, endocrine, immune, infectious, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities that would interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study.
  2. History of primary esophageal motility disorders or systemic condition affecting the esophagus (eg, scleroderma, esophageal infections).
  3. History of eosinophilic esophagitis, persistent milk protein allergy, or allergic gastroenteropathy. History or current presence of peptic ulcers; current presence of Helicobacter pylori.
  4. History of definitive acid-lowering surgery, previous esophageal surgery, or esophageal stricture is disallowed. History of fundoplication or feeding tube insertion is allowed.
  5. Treatment with full therapeutic doses of H2-receptor antagonists or sucralfate within three days prior to dosing (or a shorter washout if agreed to by Investigator and Sponsor), except for cimetidine, which must be discontinued for at least seven days prior to dosing.
  6. Treatment with a proton pump inhibitor within three days prior to dosing (or a shorter washout if agreed to by Investigator and Sponsor).
  7. Inability to have 2-week PPI therapy-free period at end of active drug treatment.
  8. Pregnancy or lactation.
  9. Known or suspected drug addiction or alcohol abuse and/or a positive urine drug screen not explained by medication list; occasional alcohol or tobacco use is not an exclusion criterion.
  10. Unwilling or unable to abide by the requirements of the study or violating the prohibitions and restrictions of the study defined in Section 9.4.
  11. Any condition which would make the patient, in the opinion of the Investigator or Sponsor, unsuitable for the study.
  12. Participation in another drug study within one month prior to dosing.
  13. A history of allergy/sensitivity to proton pump inhibitors or to their inactive ingredients.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Interventions

  • administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.

06

What researchers measure

Primary outcomes

  1. Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group

    Primary safety outcomes include adverse events, physical examinations and clinical laboratory results. AE results are presented in the table.

    Time frame: 8 weeks from randomization and end of treatment

07

Results

Posted Dec 3, 2009

Participant flow

This study was recruited at 25 centers in the US during the period of 18-Aug-2005 and 1-May-2006.

Participant flow — Overall Study
MilestoneRabeprazole 10 mgRabeprazole 20 mg
Started5457
Completed5255
Not completed22
Withdrew: Withdrawal by subject12
Withdrew: Physician decision10

Outcome measures

PrimaryTreatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group

Primary safety outcomes include adverse events, physical examinations and clinical laboratory results. AE results are presented in the table.

Time frame:
8 weeks from randomization and end of treatment
Reported as:
Number · Participants
Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group
ParticipantsRabeprazole 10 mgRabeprazole 20 mg
Diarrhea32
Nausea32
Upper abdominal pain13
Chest pain03
Upper respiratory tract infection43
Bronchitis32
Pharyngitis32
Sinusitis23
Nasopharyngitis14
Otitis media13
Headache56
Pharyngolaryngeal pain65
Cough53
Nasal congestion44
Total # subjects reporting AEs4145

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole 10 mg———
Rabeprazole 20 mg———
Most frequent serious events
Most frequent serious events
EventRabeprazole 10 mgRabeprazole 20 mg
Mood swingsNervous system disorders0/541/57
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRabeprazole 10 mgRabeprazole 20 mg
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders6/545/57
HeadacheNervous system disorders5/546/57
CoughRespiratory, thoracic and mediastinal disorders5/543/57
Upper respiratory tract infectionInfections and infestations4/543/57
Nasal congestionRespiratory, thoracic and mediastinal disorders4/544/57
NasopharyngitisInfections and infestations1/544/57
DiarrheaGastrointestinal disorders3/542/57
NauseaGastrointestinal disorders3/542/57
BronchitisInfections and infestations3/542/57
PharyngitisInfections and infestations3/542/57

Baseline characteristics

Age Continuous
Age Continuous(years)Rabeprazole 10 mgRabeprazole 20 mgTotal
Mean14.2 ± 1.314.1 ± 1.514.2 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)Rabeprazole 10 mgRabeprazole 20 mgTotal
Female272653
Male273158
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Rabeprazole 10 mgRabeprazole 20 mgTotal
Asian000
Black or African American415
White4753100
Hispanic123
Other213
Region of Enrollment
Region of Enrollment(participants)Rabeprazole 10 mgRabeprazole 20 mgTotal
United States5457111
08

Study locations

25 sites
  • Longmont Medical Research Network
    Longmont, Colorado 80501, United States
  • Nova Southeastern University
    Fort Lauderdale, Florida 33328, United States
  • Babies and Beyond Peds
    New Port Richey, Florida 34652, United States
  • Dr. Patricia Barrington, Dr. B. Abraham, PC
    Snellville, Georgia 30039, United States
  • Multi-specialty Clinical Research
    Hoffman Estates, Illinois 60194, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Professional Clinical Research
    Cadillac, Michigan 49601, United States
  • Community Pediatric Associates
    Kalamazoo, Michigan 49008, United States
  • The Center for Human Nutrition
    Omaha, Nebraska 68105, United States
  • Children's Hospital of Buffalo - Digestive Disease And Nutrition Center
    Buffalo, New York 14222, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Pediatric Associates of Mount Carmel, Inc.
    Cincinnati, Ohio 45245, United States
  • Pediatric Associates of Mt. Carmel
    Cincinnati, Ohio 45245, United States
  • University of Pediatrics
    Mason, Ohio 45040, United States
  • Center for Children's Digestive Health
    Youngstown, Ohio 44514, United States
  • Pharmacotherapy Research Associates
    Zanesville, Ohio 43701, United States
  • Biomedical Research Associates
    Shippensburg, Pennsylvania 17257, United States
  • DeGarmo Institute of Medicine Research
    Greer, South Carolina 29651, United States
  • Focus Research Group
    Hendersonville, Tennessee 37075, United States
  • ProMed Healthcare
    Johnson City, Tennessee 37601, United States
  • NE Ohio University College of Medicine
    Lebanon, Tennessee 37087, United States
  • Southwest Children's Research Associates
    San Antonio, Texas 78229, United States
  • Alpine Medical Group
    Salt Lake City, Utah 84102, United States
  • Rockwood Clinic North
    Spokane, Washington 99202, United States
  • Marshall University
    Huntington, West Virginia 25701, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of May 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2005
First posted
Aug 22, 2005
Start
Aug 2005
Primary completionActual
May 2006
CompletionActual
Jul 2006
Results first posted
Dec 3, 2009
Last update
Dec 3, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00132496
Lead sponsor
Eisai Inc.
First posted
Aug 22, 2005
Start date
Aug 2005
Primary completion
May 2006
Completion
Jul 2006
Results posted
Dec 3, 2009
Last update
Dec 3, 2009

Study contacts

Yufang Lu
study director · Eisai Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion